- Home
- RARE vs HCM Comparison
RARE vs HCM Comparison
Compare RARE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | HCM |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | HCM |
|---|---|---|
| Price | $23.18 | $14.53 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 19 | 1 |
| Target Price | ★ $66.32 | $13.75 |
| AVG Volume (30 Days) | ★ 2.1M | 22.0K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | N/A |
| Revenue This Year | $17.23 | N/A |
| Revenue Next Year | $36.13 | $16.12 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.41 | $11.51 |
| 52 Week High | $43.22 | $19.50 |
Technical Indicators
Market Signals| Indicator | RARE | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 41.92 |
| Support Level | $22.00 | $14.15 |
| Resistance Level | $25.46 | $14.63 |
| Average True Range (ATR) | 1.29 | 0.43 |
| MACD | 0.25 | -0.06 |
| Stochastic Oscillator | 72.03 | 12.96 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.